CYP2C19基因多态性检测的临床实验室性能验证
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

甘肃省科技计划项目(20JR5RA312);兰州大学第二医院“萃英科技创新”计划项目(CY2018-QN06);甘肃省教育厅创新能力提升项目(2019B-018)。


Performance verification for detection of CYP2C19 gene polymorphism in clinical laboratory
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的?对人细胞色素P450酶等位基因(CYP2C19)多态性检测试剂盒进行性能验证。方法?根据中国合格评定国家认可委员会CNAS-GL039:2019《分子诊断检验程序性能验证指南》相关要求,结合试剂盒说明书,从符合率、精密度、检出限和抗干扰能力4个方面对“人CYP2C19基因多态性检测试剂盒(荧光PCR法)”进行性能验证。符合率验证采用荧光PCR法和Sanger测序法检测;精密度验证选择杂合突变CYP2C19?c.681GA、c.636GA样本进行检测;抗干扰能力验证判断基因型检测是否受影响。结果?PCR法和Sanger测序法的检测符合率为100%;?CYP2C19?c.681 G和A等位基因的FAM和ROX荧光通道精密度检测CV值分别为3.78%、1.76%、3.76%和3.56%;CYP2C19?c.636 G和A等位基因的FAM和ROX荧光通道精密度检测CV值分别为3.08%、2.81%、3.40%和3.73%;样本最低检出限为10 ng/μL;抗干扰能力验证显示基因型可以正常检测。结论?人CYP2C19基因多态性检测试剂盒(荧光PCR法)符合ISO15189质量管理要求,可以为临床提供准确可靠的检测结果。

    Abstract:

    Objective?To verify the performance of the detection kits for human cytochrome P450 enzyme allele (CYP2C19) polymorphism.?Methods?According to China′s Conformity Assessment (CNAS) National Approval Committee CNAS-GL039: 2019 “Guidance on the Performance Verification for Molecular Diagnostic Procedures” combined with the reagent instruction, four aspects of performances for the human?CYP2C19?gene polymorphism detection kit (real-time quantitative PCR), i.e., coincidence rate, precision, detection limit and anti-interference ability, were verified. The coincidence rate was verified by fluorescence PCR and Sanger sequencing. The samples of heterozygous mutant?CYP2C19?c.681GA and c.636GA were selected to verify the precision. The anti-interference ability test was used to assess the interferences of genotype detection.?Results?The coincidence rate of the results of PCR and Sanger sequencing was 100%.?CV?values of precision verification of FAM and ROX fluorescence channels for?CYP2C19?c.681 alleles G and A were 3.78%, 1.76%, 3.76% and 3.56%, respectively.?CV?values of precision verification for FAM and ROX fluorescence channels of?CYP2C19?c.636 alleles G and A were 3.08%, 2.81%, 3.40% and 3.73%, respectively. The minimum detection limit of samples was 10 ng/μL. The verification for anti-interference ability showed that all the genotypes could be detected normally.?Conclusion?The kit for human?CYP2C19?gene polymorphism detection (real-time quantitative fluorescent PCR) conformed to ISO15189 quality management requirements and could provide accurate and reliable detection results for clinical practice.

    参考文献
    相似文献
    引证文献
引用本文

李婧,李林静,杨文娟,马青梅,张安安,杨海棠,刘泽菁,刘欣跃. CYP2C19基因多态性检测的临床实验室性能验证[J].临床检验杂志,2021,39(3):237-240

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-11-17
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-05-17
  • 出版日期: 2021-03-28
您是第位访问者  苏ICP备12051282号-1
主管单位:江苏省医学会  出版单位:临床检验杂志
单位地址:江苏省南京市中央路42号  邮编:210008
电话:025-83620683 E-MAIL:lcjyzz@163.com
技术支持:北京勤云科技发展有限公司
关闭